Hims & Hers reported Q4 2025 revenue of USD 617.8 million (+28%) with gross margin of 72%, net income of USD 20.6 million and adjusted EBITDA of USD 66.3 million. Free cash flow was no free cash flow in Q4 2025, compared with USD 59.5 million a year earlier. For FY 2025, revenue was USD 2.35 billion (+59%), with net income of USD 128.4 million and adjusted EBITDA of USD 318 million; gross margin was 74%. Subscribers ended 2025 at 2.51 million (+13%), and monthly revenue per average subscriber was USD 83 (+28%). The company highlighted 2025 launches including hormone therapies and diagnostics, introduced Labs, and said it took steps to expand internationally, including operations in the European Union and Canada and a deeper presence in the United Kingdom. Hims & Hers also said it expects to stop reporting online vs. wholesale revenue and monthly online revenue per average subscriber beginning with the quarter ending March 31, 2026, as it shifts to U.S. vs. rest-of-world revenue reporting. For FY 2026, Hims & Hers guided to revenue of USD 2.7 billion to USD 2.9 billion and adjusted EBITDA of USD 300 million to USD 375 million, excluding any potential contribution from its proposed acquisition of Eucalyptus, expected to close in mid-2026, and assuming continued ability to provide access to compounded semaglutide through its platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602231605BIZWIRE_USPR_____20260223_BW564900) on February 23, 2026, and is solely responsible for the information contained therein.